CollPlant Biotechnologies Ltd.
CLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | -0.01 | 0.08 | 0.25 |
| FCF Yield | -8.41% | -15.17% | -3.98% | -8.54% |
| EV / EBITDA | -8.78 | -2.52 | -17.93 | -8.91 |
| Quality | ||||
| ROIC | -26.91% | -19.41% | -10.81% | -24.02% |
| Gross Margin | -538.96% | -131.84% | 78.98% | -213.41% |
| Cash Conversion Ratio | 0.83 | 0.73 | 0.80 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.65% | -39.38% | 54.83% | 19.87% |
| Free Cash Flow Growth | -17.81% | -107.74% | 66.62% | 1.81% |
| Safety | ||||
| Net Debt / EBITDA | 1.72 | 2.94 | 6.53 | 2.43 |
| Interest Coverage | 0.00 | -18.80 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.91 | 0.75 | 0.64 | 1.17 |
| Cash Conversion Cycle | -1.41 | 179.11 | -0.94 | 244.65 |